Copyright
©The Author(s) 2020.
World J Clin Cases. Apr 26, 2020; 8(8): 1361-1384
Published online Apr 26, 2020. doi: 10.12998/wjcc.v8.i8.1361
Published online Apr 26, 2020. doi: 10.12998/wjcc.v8.i8.1361
Table 6 Trials assessing the effect of VSL#3 in patients with cirrhosis
Ref. | Design | n | VSL#3 intake |
Gupta et al[127], 2013 | RCT | 94 with cirrhosis | 2 mo with 9 × 1011 CFU a day |
Jayakumar et al[129], 2013 | RCT | 17 with decompensated cirrhosis; 15 completed | 2 mo with 3.6 × 1012 bacteria a day |
Rincón et al[128], 2014 | Not mentioned | 17 with cirrhosis and ascites; 12 completed | 6 wk, the dose was not clear |
Marlicz et al[130], 2016 | Not mentioned | 20 with cirrhosis (13 with compensated liver cirrhosis, 7 with decompensated liver cirrhosis), and 10 healthy controls | Daily for 28 d, the daily dose was not clear |
- Citation: Cheng FS, Pan D, Chang B, Jiang M, Sang LX. Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases. World J Clin Cases 2020; 8(8): 1361-1384
- URL: https://www.wjgnet.com/2307-8960/full/v8/i8/1361.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v8.i8.1361